About this trial

Gastroparesis is a burdensome condition that is caused by abnormal motor function of the stomach that results in delayed gastric emptying. It typically manifests with bloating, nausea, vomiting, abdominal pain, and even excessive weight loss and dehydration. The most common causes of gastroparesis are idiopathic, diabetic, medication-induced or iatrogenic (postsurgical) gastroparesis.

Implantation of a gastric neurostimulation device is a surgical option to improve gastric emptying in patients with medication-refractory gastroparesis. Enterra® system is a gastric electrical stimulation that sends mild pulses through leads implanted in the stomach wall that stimulate gastric smooth muscles and nerves in order to improve symptoms and quality of life.

Aim of the investogators' registry trial is to evaluate the feasibility and efficacy of laparoscopic gastric pacemaker implantation for electrical stimulation (Enterra® system). Primary endpoints of the study are symptom severity, health-related quality of life, and frequency of hospitalization before and after pacemaker implantation, perioperative complication rate, and cost effectiveness.

Eligibility criteria

Qualifiers

Scintigraphically proven gastroparesis

Failed conservative therapy

Severe impairment of quality of life

Written informed consent

Disqualifiers

Age < 18 years

Prior gastric resection

Trial design

Treatments tested in this trial

  • Gastric pacemaker (Enterra system) implantation

Treatment groups

50 Participants
are divided into 1 treatment group

Locations

1
Department of Functional Upper GI Surgery51103, CologneNorth Rhine-Westphalia, Germany

Sponsors and collaborators

Evangelic Hospital Kalk Cologne

Lead sponsor

University of Cologne

Sponsor institution

Enterra Medical, Inc.

Collaborator